Online citations, reference lists, and bibliographies.
← Back to Search

Amorphous Drug Delivery Systems: Molecular Aspects, Design, And Performance.

A. Kaushal, P. Gupta, A. Bansal
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The biopharmaceutical properties-especially the solubility and permeability-of a molecule contribute to its overall therapeutic efficacy. The newer tools of drug discovery have caused a shift in the properties of drug-like compounds, resulting in drugs with poor aqueous solubility and permeability, which offer delivery challenges, thus requiring considerable pharmaceutical manning. The modulation of solubility is a more viable option for enhancing bioavailability than permeability, because of the lack of "safe" approaches to enhance the latter. Solid-state manipulation in general, and amorphization in particular, are preferred ways of enhancing solubility and optimizing delivery of poorly soluble drugs. This review attempts to address the diverse issues pertaining to amorphous drug delivery systems. We discuss the various thermodynamic phenomenon such as glass transition, fragility, molecular mobility, devitrification kinetics, and molecular-level chemical interactions that contribute to the ease of formation, the solubility advantage, and the stability of amorphous drugs. The engineering of pharmaceutical alloys by solubilizing and stabilizing carriers, commonly termed solid dispersions, provide avenues for exploiting the benefits of amorphous systems. Carrier properties, mechanisms of drug release, and study of release kinetics help to improve the predictability of performance. The review also addresses the various barriers in the design of amorphous delivery systems, use of amorphous form in controlled release delivery systems, and their in vivo performance.
This paper references
10.1023/A:1015147729564
A Spectroscopic Investigation of Hydrogen Bond Patterns in Crystalline and Amorphous Phases in Dihydropyridine Calcium Channel Blockers
X. Tang (2004)
10.1016/0378-5173(94)90188-0
Assessment of the degree of disorder in crystalline solids by isothermal microcalorimetry
T. Sebhatu (1994)
10.1016/0378-5173(82)90006-0
Structure of solid dispersions in the system polyethylene glycol-griseofulvin with additions of sodium dodecyl sulphate
M. Aldén (1992)
10.1002/JPS.2600550610
Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures. IV. Chloramphenicol--urea system.
A. H. Goldberg (1966)
10.1016/0378-5173(93)90375-P
Solid dispersions of oxazepam
R. Jachowicz (1993)
10.1111/J.2042-7158.1977.TB11468.X
Solid dispersion approach for overcoming bioavailability problems due to polymorphism of nabilone, a cannabinoid derivative
Arvind Lavji Thakkar (1977)
Controlled release: mechanisms and release.
R. W. Baker (1974)
10.1111/J.1365-2125.1988.TB03318.X
Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985).
R. A. Prentis (1988)
10.1016/S0169-409X(01)00098-9
Amorphous pharmaceutical solids: preparation, characterization and stabilization.
L. Yu (2001)
10.1016/S0040-6031(01)00662-1
The use of thermal methods for predicting glass-former fragility
K. Crowley (2001)
10.1002/JPS.2600760912
Evidence for solid- and liquid-state interactions in a furosemide-polyvinylpyrrolidone solid dispersion.
C. Doherty (1987)
10.1007/BF01507758
A methode for preparing an aqueous colloidal dispersion of organic materials by using water-soluble polymers: Dispersion ofΒ-carotene by polyvinylpyrrolidone
T. Tachibana (1965)
10.1021/JS9900856
Solubility parameters as predictors of miscibility in solid dispersions.
D. Greenhalgh (1999)
10.1002/JPS.2600690720
Model of interaction of ajmaline with polyvinylpyrrolidone.
T. Hosono (1980)
10.1002/JPS.2600561005
Establishment of sink conditions in dissolution rate determinations. Theoretical considerations and application to nondisintegrating dosage forms.
M. Gibaldi (1967)
10.1016/0022-3093(95)00308-8
Organic monomeric glass formation by substituted ethylenediamine
T. Karis (1995)
10.1111/j.2042-7158.2003.tb02431.x
Physical stability and enthalpy relaxation of drug‐hydroxypropyl methylcellulose phthalate solvent change co‐precipitates
G. Sertsou (2003)
10.1211/002235702320266343
Polyamorphism: a pharmaceutical science perspective
Bruno C. Hancock (2002)
10.1557/JMR.1995.2128
Glass formation from low molecular weight organic melts
S. Kim (1995)
10.1248/CPB.35.2943
Glassy state of pharmaceuticals. II. Bioinequivalence of glassy and crystalline indomethacin.
E. Fukuoka (1987)
10.1016/0378-5173(87)90180-3
Mechanisms of dissolution of frusemide pvp solid dispersions
C. Doherty (1987)
10.1016/0022-3093(96)00151-2
Strong and fragile liquids — a brief critique
I. Hodge (1996)
10.1016/S0378-5173(01)00767-0
Influence of various drugs on the glass transition temperature of poly(vinylpyrrolidone): a thermodynamic and spectroscopic investigation.
R. Nair (2001)
10.1021/AR980007+
Attractions and Repulsions in Molecular Crystals: What Can Be Learned from the Crystal Structures of Condensed Ring Aromatic Hydrocarbons?
J. D. Dunitz (1999)
10.1002/JPS.10307
Solid-state nuclear magnetic resonance spectroscopy--pharmaceutical applications.
P. Tishmack (2003)
10.1063/1.1730566
Molecular Transport in Liquids and Glasses
M. H. Cohen (1959)
10.1016/0378-5173(87)90067-6
Dissolution rates of partially water-soluble drugs from solid dispersion systems. I. Prednisolone
R. Jachowicz (1987)
10.1248/CPB.45.1688
Comparison of nicotinamide, ethylurea and polyethylene glycol as carriers for nifedipine solid dispersion systems.
H. Suzuki (1997)
10.1016/S0378-5173(97)00274-3
Dissolution mechanism and rate of solid dispersion particles of nilvadipine with hydroxypropylmethylcellulose
K. Okimoto (1997)
10.1021/J100619A008
Dependence of the glass transition temperature on heating and cooling rate
C. T. Moynihan (1974)
10.1248/CPB.46.482
Influence of water-soluble polymers on the dissolution of nifedipine solid dispersions with combined carriers.
H. Suzuki (1998)
10.1016/0040-6031(94)01888-N
PHARMACEUTICAL APPLICATIONS OF DYNAMIC-MECHANICAL THERMAL-ANALYSIS
D. Q. Craig (1995)
10.1002/JPS.2600701211
General model for dissolution rates of n-component, nondisintegrating spheres.
G. Carmichael (1981)
10.1016/0378-5173(83)90111-4
Solid-state properties of powders in the formulation and processing of solid dosage forms
P. York (1983)
10.1002/JPS.2600740523
Absorption potential: estimating the fraction absorbed for orally administered compounds.
J. Dressman (1985)
10.1016/S0169-409X(01)00102-8
Chemical reactivity in solid-state pharmaceuticals: formulation implications.
S. Byrn (2001)
10.1080/00107516908204405
Under what conditions can a glass be formed
D. Turnbull (1969)
10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J
Intestinal permeation enhancers.
B. Aungst (2000)
10.1016/S0378-5173(01)00928-0
Solid state characterization of an neuromuscular blocking agent--GW280430A.
H. Zhu (2002)
10.1002/JPS.1033
Explanation of the crystallization rate of amorphous nifedipine and phenobarbital from their molecular mobility as measured by (13)C nuclear magnetic resonance relaxation time and the relaxation time obtained from the heating rate dependence of the glass transition temperature.
Y. Aso (2001)
10.1211/0022357021778989
Disordered drug delivery: destiny, dynamics and the Deborah number
Bruno C. Hancock (2002)
10.1201/b17873
Principles Of Polymer Systems
F. Rodriguez (1982)
10.1021/MA00171A055
Correlation between the glass transition temperatures of polymer mixtures and intermolecular force parameters
T. Kwei (1987)
10.1016/S0928-0987(00)00173-1
Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25.
G. Van den Mooter (2001)
10.1016/0022-3093(94)90321-2
Enthalpy relaxation and recovery in amorphous materials
I. Hodge (1994)
10.1016/S0378-5173(01)00751-7
Dissolution properties and anticonvulsant activity of phenytoin-polyethylene glycol 6000 and -polyvinylpyrrolidone K-30 solid dispersions.
M. Franco (2001)
10.1016/0378-5173(86)90056-6
A comparison between the in vivo serum levels and in vitro dissolution of indomethacin-polymer dispersion systems
J. E. Hilton (1986)
10.1111/j.2042-7158.1976.tb02840.x
The influence of polyvinylpyrrolidone on the dissolution and bioavailability of hydrochlorothiazide
O. Corrigan (1976)
10.1111/j.2042-7158.1986.tb04525.x
The effect of the molecular weight of polyethylene glycol on the bioavailability of paracetamol‐polyethylene glycol solid dispersions
J. L. Vila-jato (1986)
10.1016/0378-5173(94)90308-5
Lyoavailability of nordazepam solid dispersions in relation with phase diagrams
A. Moussaoui (1994)
10.1016/s0378-5173(96)04687-x
Properties of solid dispersions of piroxicam in polyvinylpyrrolidone.
V. Tantishaiyakul (1999)
10.1081/DDC-120006431
Evaluation of Solid Dispersions of Clofazimine
Ajit S. Narang (2002)
10.3109/03639049609058566
Dissolution behavior of griseofulvin solid dispersions using polyethylene glycol, talc, and their combination as dispersion carriers
W. Y. Lo (1996)
10.1021/CR60135A002
The Nature of the Glassy State and the Behavior of Liquids at Low Temperatures.
Walter. Kauzmann (1948)
10.1016/S0378-5173(02)00647-6
Investigations on the predictability of the formation of glassy solid solutions of drugs in sugar alcohols.
M. Langer (2003)
10.1023/A:1015888520352
Physical Characterization of Pharmaceutical Solids
H. Brittain (2004)
10.1016/1359-6446(96)10020-9
Design principles for orally bioavailable drugs
M. A. Navia (1996)
10.1002/JPS.10026
Improvement of solubility and oral bioavailability of a poorly water-soluble drug, TAS-301, by its melt-adsorption on a porous calcium silicate.
Masahiro Kinoshita (2002)
10.1002/(SICI)1520-6017(200003)89:3<417::AID-JPS12>3.0.CO;2-V
Interpretation of relaxation time constants for amorphous pharmaceutical systems.
S. Shamblin (2000)
Influence of Diluent and of Copolymer Composition on the Glass Temperature of a Poly-mer System
T. Fox (1956)
10.1016/S0378-5173(01)00709-8
A comparison of alternative polymer excipients and processing methods for making solid dispersions of a poorly water soluble drug.
E. Broman (2001)
10.1016/0378-5173(94)00195-B
Preformulation study of etoposide: II. Increased solubility and dissolution rate by solid-solid dispersions
J. Shah (1995)
10.1248/CPB.37.1047
Glassy state of pharmaceuticals. III. Thermal properties and stability of glassy pharmaceuticals and their binary glass systems.
E. Fukuoka (1989)
10.3109/03639048209022120
Chlorothiazide-Polyvinylpyrrolidone (PVP) Interactions: Influence on Membrane Permeation (Everted Rat Intestine) and Dissolution
K. M. O'driscoll (1982)
10.1016/0378-5173(94)90320-4
Physical characteristics and dissolution kinetics of solid dispersions of ketoprofen and polyethylene glycol 6000
M. Margarit (1994)
10.1016/0378-5173(79)90099-1
Dissolution properties of polyethylene glycols and polyethylene glycol-drug systems
O. Corrigan (1979)
10.1063/1.1733201
On a General Relation Involving the Glass Temperature and Coefficients of Expansion of Polymers
R. Simha (1962)
10.3109/03639049109074395
Improved Aqueous Dissolution of Clofazimine from Coevaporates Using Polyvinylmethyl Ether/Maleic Anhydride Copolymer
T. R. Krishnan (1991)
10.1016/S0031-6865(97)00051-4
Dissolution properties of praziquantel--PVP systems.
S. K. el-Arini (1998)
10.1023/A:1021453810624
Enthalpy Relaxation Studies of Celecoxib Amorphous Mixtures
Vasu Kumar Kakumanu (2004)
10.1016/J.ADDR.2003.10.009
Phase transformation considerations during process development and manufacture of solid oral dosage forms.
G. Zhang (2004)
10.1002/1521-3765(20000616)6:12<2288::AID-CHEM2288>3.0.CO;2-D
A molecular dynamics study of the structure and evolution of the 4,4'-bis(diphenylhydroxymethyl)biphenyl/acetone host-guest system
Gavezzotti (2000)
10.3109/03639048509056896
Mechanisms of Dissolution of Fast Release Solid Dispersions
O. Corrigan (1985)
10.1016/S0169-409X(01)00100-4
Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes.
K. Morris (2001)
10.1016/S0378-5173(98)00260-9
Enhanced dissolution of furosemide by coprecipitating or cogrinding with crospovidone
Sang-Chul Shin (1998)
10.1016/J.ADDR.2003.10.008
Drug polymorphism and dosage form design: a practical perspective.
Dharmendra Singhal (2004)
10.1023/A:1015834715152
The Relationship Between the Glass Transition Temperature and Water Vapor Absorption by Poly(vinylpyrrolidone)
C. A. Oksanen (2004)
10.1126/science.267.5206.1924
Formation of Glasses from Liquids and Biopolymers
C. Angell (1995)
10.1016/S1056-8719(00)00107-6
Drug-like properties and the causes of poor solubility and poor permeability.
C. Lipinski (2000)
10.1016/0022-2860(94)08233-2
Hydrogen bonds in crystalline carbohydrates A variable-temperature FT-IR study
E. Lutz (1994)
10.3109/03639049509070872
DEVELOPMENT OF DICLOFENAC SODIUM CONTROLLED RELEASE SOLID DISPERSIONS BY SPRAY DRYING USING OPTIMIZATION STRATEGY I. POWDER FORMULATION
P. Dangprasirt (1995)
10.1002/JPS.2600800517
Enhancement of dissolution and absorption of mefenamic acid by egg albumin.
T. Imai (1991)
10.1021/MP034009U
GSSI, a general model for solute-solvent interactions. 1. Description of the model.
F. Deanda (2004)
10.1002/JPS.2600750202
Mixing-tank model for predicting dissolution rate control or oral absorption.
J. Dressman (1986)
10.1016/S0378-5173(97)00279-2
Enhanced release of oxazepam from tablets containing solid dispersions
R. Jachowicz (1997)
10.1002/JPS.2600600902
Pharmaceutical applications of solid dispersion systems.
W. Chiou (1971)
10.1081/DDC-120015357
Lonidamine Solid Dispersions: In Vitro and In Vivo Evaluation
G. Palmieri (2002)
10.1081/DDC-100101274
PVP Solid Dispersions for the Controlled Release of Furosemide from a Floating Multiple-Unit System
V. Iannuccelli (2000)
10.1002/JPS.2600840621
Dielectric analysis in the characterization of amorphous pharmaceutical solids. 1. Molecular mobility in poly(vinylpyrrolidone)-water systems in the glassy state.
S. Duddu (1995)
10.1002/JPS.10115
Effects of mechanical processing on phase composition.
H. Brittain (2002)
10.1016/S0378-5173(02)00577-X
Evaluation of solid dispersion particles prepared with SEDS.
A. Juppo (2003)
10.1023/A:1012026911459
Molecular Mobility of Supercooled Amorphous Indomethacin, Determined by Dynamic Mechanical Analysis
V. Andronis (2004)
10.1021/ja00851a051
Enhancement of a chemical reaction rate by proper orientation of reacting molecules in the solid state
C. N. Sukenik (1975)
10.1016/0022-3093(91)90266-9
Relaxation in liquids, polymers and plastic crystals — strong/fragile patterns and problems☆
C. Angell (1991)
10.1211/0022357991772277
Improving the Oral Bioavailability of Albendazole in Rabbits by the Solid Dispersion Technique
N. Kohri (1999)
10.1023/B:PHAM.0000008037.57884.11
Quantitative Biopharmaceutics Classification System: The Central Role of Dose/Solubility Ratio
E. Rinaki (2004)
Phase equilibria and dissolution rates of indomethacin-polyethylene glycol 6000 solid dispersions.
Ford Jl (1978)
10.1073/PNAS.92.15.6675
The old problems of glass and the glass transition, and the many new twists.
C. Angell (1995)
10.1111/j.2042-7158.1982.tb04689.x
Mechanism of drug dissolution rate enhancement from β‐cyclodextrin‐drug systems
O. Corrigan (1982)
Introduction to biopharmaceutics
M. Gibaldi (1971)
10.3109/03639048509087762
Dissolution Rates of Carbamazepine and Nitrazepam Utilizing Sugar Solid Dispersion System
M. Attia (1985)
10.1088/1367-2630/3/1/317
Molecular solid glasses: new insights into frustrated systems
S. Pilla (2001)
10.1002/JPS.2600551138
New method of solid-state dispersion for increasing dissolution rates.
M. Mayersohn (1966)
10.1002/POL.1961.1205015421
Viscosity and glass temperature relations for polymer‐diluent systems
F. N. Kelley (1961)
10.1002/JPS.10404
Prediction of the relaxation behavior of amorphous pharmaceutical compounds. I. Master curves concept and practice.
L. R. Hilden (2003)
10.1016/S0378-5173(98)00281-6
Studies in dissolution enhancement of atenolol. Part I
M. Moneghini (1998)
10.1002/POL.1979.180170701
Isobaric volume and enthalpy recovery of glasses. II. A transparent multiparameter theory
A. Kovács (1979)
10.1002/1520-6017(200010)89:10<1325::AID-JPS10>3.0.CO;2-5
Crystallization inhibition in solid dispersions of MK-0591 and poly(vinylpyrrolidone) polymers.
K. Khougaz (2000)
10.1021/BK-1976-0033.CH004
Importance of Solute Partitioning on the Kinetics of Drug Release from Matrix Systems
T. Roseman (1976)
10.1016/S0378-5173(99)00112-X
Physicochemical characterization and in vivo properties of Zolpidem in solid dispersions with polyethylene glycol 4000 and 6000.
G. Trapani (1999)
10.1016/J.ADDR.2003.10.007
Impact of solid state properties on developability assessment of drug candidates.
L. Huang (2004)
10.1016/S0168-3659(98)00145-X
Control of medicine release from solid dispersion composed of the poly(ethylene oxide)-carboxyvinylpolymer interpolymer complex by varying molecular weight of poly(ethylene oxide).
T. Ozeki (1999)
10.3109/03639049509026667
Controlled Nifedipine Release from Microcapsules of its Dispersions in PVP-MCC and HPC-MCC
K. Chowdary (1995)
10.1021/JS9800174
Sugar-polymer hydrogen bond interactions in lyophilized amorphous mixtures.
L. Taylor (1998)
10.1002/JPS.2600671126
Glass formation in barbiturates and solid dispersion systems of barbiturates with citric acid.
Murray Summers (1978)
10.1002/(SICI)1520-6017(200001)89:1<128::AID-JPS13>3.0.CO;2-Z
Physical characteristics and chemical degradation of amorphous quinapril hydrochloride.
Y. Guo (2000)
10.1081/DDC-100102169
Thermal behavior and dissolution properties of naproxen from binary and ternary solid dispersions.
P. Mura (1999)
10.1016/S0378-5173(00)00437-3
Solid dispersion of ketoprofen in pellets.
R. Jachowicz (2000)
10.1002/JPS.2600581218
Preparation and dissolution characteristics of several fast-release solid dispersions of griseofulvin.
W. Chiou (1969)
10.1023/A:1011087012826
Detection of Low Levels of the Amorphous Phase in Crystalline Pharmaceutical Materials by Thermally Stimulated Current Spectrometry
G. Venkatesh (2004)
10.1023/A:1012167410376
Spectroscopic Characterization of Interactions Between PVP and Indomethacin in Amorphous Molecular Dispersions
L. Taylor (2004)
10.1002/JPS.2600541003
Dissolution rates of polyphase mixtures.
W. Higuchi (1965)
10.1016/S0378-5173(98)00338-X
The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems.
D. Craig (1999)
10.1111/J.2042-7158.1978.TB13306.X
Dissolution of solid dispersions: the glutethimide‐Renex 650 melt system
J. L. Ford (1978)
10.1016/0378-5173(95)04114-1
Enhancement of dissolution of glyburide by solid dispersion and lyophilization techniques
G. Betageri (1995)
10.1002/JPS.10020
Improvement of dissolution and oral absorption of ER-34122, a poorly water-soluble dual 5-lipoxygenase/cyclooxygenase inhibitor with anti-inflammatory activity by preparing solid dispersion.
Ikuo Kushida (2002)
10.1016/S1461-5347(98)00097-2
Physical chemical properties of oral drug candidates in the discovery and exploratory development settings
W. Curatolo (1998)
10.1016/0378-5173(89)90037-9
Sustained release solid dispersions of indomethacin with Eudragit RS and RL
Marianne P. Oth (1989)
10.1021/JS980403L
Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs.
A. T. Serajuddin (1999)
10.1016/0378-5173(86)90183-3
Characteristics of the in vitro release of ibuprofen from polyvinylpyrrolidone solid dispersions
N. Najib (1986)
10.1021/MA60061A021
A Classical Thermodynamic Discussion of the Effect of Composition on Glass-Transition Temperatures
P. Couchman (1978)
10.4028/WWW.SCIENTIFIC.NET/MSF.19-20.11
Glass Forming Ability Criterion
M. Saad (1987)
10.1002/JPS.10522
Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow-dissolving polymers.
K. Six (2004)
10.1002/JPS.2600570524
Dissolution of salicylic acid and polyvinylpyrrolidone from compressed mixtures.
M. Gibaldi (1968)
10.1002/JPS.10526
Molecular mobility-based estimation of the crystallization rates of amorphous nifedipine and phenobarbital in poly(vinylpyrrolidone) solid dispersions.
Y. Aso (2004)
10.1016/0378-5173(96)04586-3
Preparation, dissolution and characterization of albendazole solid dispersions
S. Torrado (1996)
10.1021/JP990152K
A Criterion for Evaluating the Thermal Stability of Glasses
K. Cheng (1999)
10.1016/S0378-5173(01)00891-2
The mechanisms of drug release from solid dispersions in water-soluble polymers.
D. Craig (2002)
Release of carbamazepine from solid dispersions with polyvinylpyrrolidone/vinylacetate copolymer (PVP/VA)
G. Zingone (1994)
10.1016/0378-5173(95)04245-8
Effect of particle size on the available surface area of nifedipine from nifedipine-polyethylene glycol 6000 solid dispersions
Ching-Wei Lin (1996)
10.1002/CHIN.197717110
A kinetic and x-ray diffraction study of the solid state rearrangement of methyl p-dimethylaminobenzenesulfonate. Reaction rate enhancement due to proper orientation in a crystal
C. N. Sukenik (1977)
10.1021/JM020017N
Molecular properties that influence the oral bioavailability of drug candidates.
D. Veber (2002)
The current status of solid dispersions.
Ford Jl (1986)
10.1016/S0958-1669(99)00062-2
Chemoinformatics - predicting the physicochemical properties of 'drug-like' molecules.
J. F. Blake (2000)
10.1016/S0378-5173(98)00245-2
Effect of chitosan and chitosan glutamate enhancing the dissolution properties of the poorly water soluble drug nifedipine
A. Portero (1998)
10.3109/03639049209069300
Elaboration and Physical Study of an Oxodipine Solid Dispersion in Order to formulate Tablets
F. Guillaume (1992)
10.1016/0378-5173(86)90142-0
The properties of solid dispersions of indomethacin or phenylbutazone in polyethylene glycol
J. L. Ford (1986)
10.3109/03639048809151928
Dissolution Rate of Griseofulvin from Solid Dispersions with Poly(Vinylmethylether/Maleic Anhydride)
Cristina Flego (1988)
10.1023/A:1018967424392
The Influence of Polymer Glass Transition Temperature and Molecular Weight on Drug Release from Tablets Containing Poly(DL-lactic Acid)
M. O. Omelczuk (2004)
10.1002/JPS.2600580503
Dissolution rates of high energy polyvinylpyrrolidone (PVP)-sulfathiazole coprecipitates.
A. Simonelli (1969)
10.1002/JPS.2600670609
Quantitative crystallinity determinations for beta-lactam antibiotics by solution calorimetry: correlations with stability.
M. J. Pikal (1978)
Dissolution of acetylsalicylic acid from acetylsalicylic acid-polyethylene glycol 6000 coprecipitates.
Asker Af (1975)
10.3109/03639048509056885
Solid Dispersion Controlled Release: Effect of Particle Size, Compression Force and Temperature
A. Fassihi (1985)
Phase solubility techniques
T. Higuchi (1965)
10.1002/JPS.3030490417
Some pharmaceutical properties of novobiocin.
J. Mullins (1960)
10.1021/MP034006H
Molecular properties of WHO essential drugs and provisional biopharmaceutical classification.
N. A. Kasim (2004)
10.1016/s0169-409x(96)00423-1
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.
C. Lipinski (2001)
10.1021/JS970224O
Determination of the glass properties of D-mannitol using sorbitol as an impurity.
L. Yu (1998)
10.1016/S0169-409X(01)00101-6
Characterization of the solid-state: spectroscopic techniques.
D. Bugay (2001)
10.1002/JPS.2600820108
Hygroscopic stability and dissolution properties of spray-dried solid dispersions of furosemide with Eudragit.
M. Otsuka (1993)
10.1016/0378-5173(93)90037-G
Dissolution kinetics of piroxicam in solid dispersions with polyethylene glycol 4000
M. Fernández (1993)
10.1016/S0169-409X(00)00118-6
Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future.
R. Mueller (2001)
10.1002/JPS.2600540902
Solubilized systems in pharmacy.
J. Swarbrick (1965)
10.1081/DDC-100100993
Investigation of Dissolution Enhancement of Itraconazole by Solid Dispersion in Superdisintegrants
K. P. Chowdary (2000)
10.1021/I360029A002
The Universality of the Solubility Parameter
C. Hansen (1969)
10.1007/BF01070945
Biopharmaceutical and physicochemicai studies on reserpine-polyvinylpyrrolidone coprecipitates
E. Stupak (2005)
Bioavailability and erosive activity of solid dispersions of some non-steroidal anti-inflammatory drugs
E. Ramadan (1987)
10.1016/0378-5173(80)90130-1
Drug membrane transport enhancement using high energy drug polyvinylpyrrolidone (PVP) co-precipitates
O. Corrigan (1980)
10.3109/03639049809097274
Development of diclofenac sodium controlled release solid dispersion powders and capsules by freeze drying technique using ethylcellulose and chitosan as carriers.
P. Dangprasirt (1998)
10.1016/0378-5173(95)00083-U
The use of gravimetric studies to assess the degree of crystallinity of predominantly crystalline powders
G. Buckton (1995)
10.1126/SCIENCE.11539186
Structural transitions in amorphous water ice and astrophysical implications.
P. Jenniskens (1994)
10.1016/0378-5173(85)90140-1
Evaluation of two concepts of crystallinity using calcium gluceptate as a model compound
R. Suryanarayanan (1985)
Chemistry of the solid state
W. Garner (1955)
10.1002/JPS.2600840814
Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates.
M. Yoshioka (1995)
10.1248/CPB.9.866
Studies on Absorption of Eutectic Mixture. I. A Comparison of the Behavior of Eutectic Mixture of Sulfathiazole and that of Ordinary Sulfathiazole in Man.
K. Sekiguchi (1961)
10.1111/j.2042-7158.1985.tb03064.x
Promoting effect of the new chymotrypsin inhibitor FK‐448 on the intestinal absorption of insulin in rats and dogs
S. Fujii (1985)
10.1002/JPS.2600601031
Increased dissolution rates of water-insoluble cardiac glycosides and steroids via solid dispersions in polyethylene glycol 6000.
W. Chiou (1971)
10.1021/JP953538D
Supercooled Liquids and Glasses
M. Ediger (1996)
The glassy state in foods
J. M. Blanshard (1993)
10.1016/S0939-6411(00)00076-X
Improving drug solubility for oral delivery using solid dispersions.
C. Leuner (2000)
10.1002/JPS.2600650310
Dissolution rates of high energy sulfathiazole--povidone coprecipitates II: characterization of form of drug controlling its dissolution rate via solubility studies.
A. Simonelli (1976)
10.1016/0378-5173(95)00026-F
Influence of the preparation method of solid dispersions on their dissolution rate: Study of triamterene-d-mannitol system
M. Arias (1995)
10.1023/A:1020905412654
Hydrogen Bonding with Adsorbent During Storage Governs Drug Dissolution from Solid-Dispersion Granules
M. K. Gupta (2004)
10.1016/S0378-5173(02)00196-5
Stabilization of amorphous indomethacin by co-grinding in a ternary mixture.
T. Watanabe (2002)
10.1016/S0378-5173(01)00776-1
Stability of amorphous indomethacin compounded with silica.
T. Watanabe (2001)
10.1016/S0378-5173(97)00167-1
Application of the solid dispersion method to the controlled release of medicine. IX. Difference in the release of flurbiprofen from solid dispersions with poly(ethylene oxide) and hydroxypropylcellulose and the interaction between medicine and polymers
T. Ozeki (1997)
10.1248/CPB.39.465
Application of the Solid Dispersion Method to Controlled Release of Medicine. I. Controlled Release of Water Soluble Medicine by Using Solid Dispersion
H. Yuasa (1991)
10.1016/J.MSER.2004.03.001
Bulk metallic glasses
W. Wang (2004)
10.1016/0022-3093(72)90269-4
A kinetic treatment of glass formation
D. R. Uhlmann (1972)
10.1111/J.1151-2916.1925.TB16731.X
ANALYSIS OF RECENT MEASUREMENTS OF THE VISCOSITY OF GLASSES
Gordon S. Fulcher (1925)
10.1023/A:1016212804288
A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
G. Amidon (2004)
Coprocessed excipients for solid dosage forms
S. K. Nachaegari (2004)
10.5860/choice.35-4499
Physical chemistry of surfaces
A. Adamson (1960)
10.1038/35014711
Glass transition: Hard knock for thermodynamics
S. Torquato (2000)
10.1016/S1359-6446(99)01451-8
Computational methods for the prediction of 'drug-likeness'
Clark (2000)
10.1016/0378-5173(92)90368-C
THE DISSOLUTION OF NORTRIPTYLINE HCL FROM POLYETHYLENE-GLYCOL SOLID DISPERSIONS
D. Craig (1992)
10.1002/JPS.2600821008
Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism.
B. Aungst (1993)
10.1002/JPS.2600640805
Characterization of habits and crystalline modification of solids and their pharmaceutical applications.
J. Haleblian (1975)
10.1038/310393A0
‘Melting ice’ I at 77 K and 10 kbar: a new method of making amorphous solids
O. Mishima (1984)
10.1016/J.ADDR.2003.10.005
General principles of pharmaceutical solid polymorphism: a supramolecular perspective.
Barbara Rodríguez-Spong (2004)
10.1023/A:1007516718048
What is the True Solubility Advantage for Amorphous Pharmaceuticals?
Bruno C. Hancock (2004)
10.1023/A:1016292416526
Molecular Mobility of Amorphous Pharmaceutical Solids Below Their Glass Transition Temperatures
Bruno C. Hancock (2004)



This paper is referenced by
10.1208/s12249-012-9918-9
Soluble Itraconazole in Tablet Form Using Disordered Drug Delivery Approach: Critical Scale-up Considerations and Bio-equivalence Studies
S. Swaminathan (2012)
10.1016/j.ijpharm.2018.07.063
Aspartame as a co‐former in co‐amorphous systems
Wenqi Wu (2018)
10.1016/j.ejpb.2011.08.005
Preparation and solid-state characterization of ball milled saquinavir mesylate for solubility enhancement.
M. Branham (2012)
10.1016/J.IJPHARM.2005.12.007
Characterization of the molecular distribution of drugs in glassy solid dispersions at the nano-meter scale, using differential scanning calorimetry and gravimetric water vapour sorption techniques.
D. V. van Drooge (2006)
10.15272/AJBPS.V2I11.68
Formulation and Characterization of Novel Solid Dispersions of Hydrochlorothiazide bySolvent Evaporation Technique
Abhay N Padalkar (2012)
10.1002/aoc.6035
Inclusion of sulfamethoxazole in a novel CuFe2O4 nanoparticles/mesoporous silica‐based nanocomposite: Release kinetics and antibacterial activity
Fatemeh Mehrabi (2020)
10.1155/2013/848043
Formulation Strategies to Improve the Bioavailability of Poorly Absorbed Drugs with Special Emphasis on Self-Emulsifying Systems
S. Gupta (2013)
10.1002/JPS.21212
Engineering of pharmaceutical materials: an industrial perspective.
Kwok Chow (2008)
SOLID DISPERSIONS: AN INDUSTRIALLY FEASIBLE ALTERNATIVE APPROACH TO FORMULATE BRICK DUST MOLECULES
Nikhil Kumar Sachan (2011)
The Effects of Temperature and Dissolution Media on Crystallization of Amorphous Drugs and Potential Effects on Predicting Bioavailability
Mary S. Kleppe (2018)
10.1016/j.ijpharm.2012.08.031
Development of novel microprecipitated bulk powder (MBP) technology for manufacturing stable amorphous formulations of poorly soluble drugs.
N. Shah (2012)
10.1016/j.jpba.2013.01.042
Multivariate analysis of quaternary carbamazepine-saccharin mixtures by X-ray diffraction and infrared spectroscopy.
R. Caliandro (2013)
10.1016/J.JNONCRYSOL.2018.10.046
Dielectric spectroscopic studies of three important active pharmaceutical ingredients - clofoctol, droperidol and probucol
M. Sahra (2019)
STABILITY OF DRUGS AND DRUG PRODUCTS
I. Ahmad (2016)
10.1002/9780470571224.PSE524
Amorphous Solid Dispersion Screening
Ann W. Newman (2015)
10.1016/j.ijpharm.2014.11.002
Counter-intuitive effect of non-crystallizing sugars on the crystallization of gemcitabine HCl in frozen solutions.
Bhushan Munjal (2015)
10.1016/J.FOODHYD.2019.04.004
Encapsulation of allopurinol by glucose cross-linked gelatin/zein nanofibers: Characterization and release behavior
Lingli Deng (2019)
10.1016/j.xphs.2017.10.041
Biorelevant Media Slows the Solution-Mediated Phase Transformation of Amorphous Spironolactone.
Mary S. Kleppe (2018)
Influence of excipients on stabilisation of amorphous cefuroxime axetil under process conditions of compression and coating.
Nadia Abder Rahman Ali Ghazal (2005)
10.1208/s12249-012-9795-2
Evaluation of Drug Load and Polymer by Using a 96-Well Plate Vacuum Dry System for Amorphous Solid Dispersion Drug Delivery
Po-Chang Chiang (2012)
10.1002/JPS.21252
Calorimetric relaxation and the glass-liquid temperature range of acetaminophen-nifedipine alloys.
G. P. Johari (2008)
Formulation And Evaluation Of Controlled Release Matrices Of Selected Propionic Acid Derivatives
Wahab Abdul (2012)
Advanced physical characterisation of milled pharmaceutical solids
D. Wang (2012)
10.1002/jps.23025
Solution-mediated phase transformation: significance during dissolution and implications for bioavailability.
Kristyn Greco (2012)
10.1533/9781908818683.169
Experimental techniques involved in the development of oral insulin carriers
Thundiparambil Azeez Sonia (2015)
10.1016/j.ijpharm.2016.10.043
Co amorphous systems: A product development perspective.
Rahul B Chavan (2016)
10.3109/03639045.2014.884120
High-energy ball milling of saquinavir increases permeability across the buccal mucosa
Sanjeev Rambharose (2014)
Characterisation and processing of amorphous binary mixtures with low glass transition temperature
Pekka Hoppu (2008)
KINETIC STUDIES ON CRYSTALLIZATION PROCESS OF AMORPHOUS VILAZODONE HYDROCHLORIDE
Praveen Kumar Ch (2014)
SOLID DISPERSION: A REVIEW
Xitiz Dogra (2015)
Design of freeze-dried formulations for the enhancement of drug release
Abdulmalik Alqurshi (2016)
From Polymorph Screening to Dissolution Testing - Solid Phase Analysis during Pharmaceutical Development and Manufacturing
J. Aaltonen (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar